Evaluation and medical management of benign prostatic hyperplasia

被引:25
作者
Beckman, TJ
Mynderse, LA
机构
[1] Mayo Clin, Coll Med, Mens Hlth Ctr Urol, Div Gen Internal Med, Rochester, MN 55905 USA
[2] Mayo Clin, Coll Med, Dept Urol, Rochester, MN 55905 USA
关键词
D O I
10.4065/80.10.1356
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Benign prostatic hyperplasia (BPH) is common among aging men. Untreated BPH may lead to complications Including urinary tract infection, acute urinary retention, and obstructive nephropathy. Diagnosing BPH can be challenging because lower urinary tract symptoms are found in conditions other than BPH, and prostate size correlates poorly with symptoms of obstruction. Nonetheless, a careful medical history and physical examination, along with prudent use of diagnostic tests, can yield an accurate diagnosis. We review the evaluation of men with suspected BPH and indications for referral to a urologist for invasive therapy. We also review supporting evidence and treatment considerations for saw palmetto and the 2 major classes of prescription medications, alpha(1)-adrenergic antagonists and 5 alpha-reductase inhibitors.
引用
收藏
页码:1356 / 1362
页数:7
相关论文
共 48 条
[1]
Improvement of pressure flow parameters with finasteride is greater in men with large prostates [J].
Abrams, P ;
Schäfer, W ;
Tammela, TLJ ;
Barrett, DM ;
Hedlund, H ;
Rollema, HJ ;
Matos-Ferreira, A ;
Nordling, J ;
Bruskewitz, R ;
Andersen, JT ;
Hald, T ;
Miller, P ;
Kirby, R ;
Mustonen, S ;
Cannon, A ;
Jacobsen, CA ;
Gormley, GJ ;
Malice, MP ;
Bach, MA .
JOURNAL OF UROLOGY, 1999, 161 (05) :1513-1517
[2]
Safety and tolerability of the dual 5α-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia [J].
Andriole, GL ;
Kirby, R .
EUROPEAN UROLOGY, 2003, 44 (01) :82-88
[3]
NATURAL-HISTORY OF BENIGN PROSTATIC HYPERPLASIA AND RISK OF PROSTATECTOMY - THE BALTIMORE LONGITUDINAL-STUDY OF AGING [J].
ARRIGHI, HM ;
METTER, EJ ;
GUESS, HA ;
FOZZARD, JL .
UROLOGY, 1991, 38 (01) :4-8
[5]
Management of benign prostatic hyperplasia [J].
Barry, M ;
Roehrborn, C .
ANNUAL REVIEW OF MEDICINE, 1997, 48 :177-189
[6]
RELATIONSHIP OF SYMPTOMS OF PROSTATISM TO COMMONLY USED PHYSIOLOGICAL AND ANATOMICAL MEASURES OF THE SEVERITY OF BENIGN PROSTATIC HYPERPLASIA [J].
BARRY, MJ ;
COCKETT, ATK ;
HOLTGREWE, HL ;
MCCONNELL, JD ;
SIHELNIK, SA ;
WINFIELD, HN .
JOURNAL OF UROLOGY, 1993, 150 (02) :351-358
[7]
THE AMERICAN-UROLOGICAL-ASSOCIATION SYMPTOM INDEX FOR BENIGN PROSTATIC HYPERPLASIA [J].
BARRY, MJ ;
FOWLER, FJ ;
OLEARY, MP ;
BRUSKEWITZ, RC ;
HOLTGREWE, HL ;
MEBUST, WK ;
COCKETT, ATK ;
BLAIVAS, JG ;
WEIN, AJ .
JOURNAL OF UROLOGY, 1992, 148 (05) :1549-1557
[8]
Dihydrotestosterone and the concept of 5α-reductase inhibition in human benign prostatic hyperplasia [J].
Bartsch, G ;
Rittmaster, RS ;
Klocker, H .
EUROPEAN UROLOGY, 2000, 37 (04) :367-380
[9]
THE DEVELOPMENT OF HUMAN BENIGN PROSTATIC HYPERPLASIA WITH AGE [J].
BERRY, SJ ;
COFFEY, DS ;
WALSH, PC ;
EWING, LL .
JOURNAL OF UROLOGY, 1984, 132 (03) :474-479
[10]
Meta-analysis of clinical trials of Permixon in the treatment of symptomatic benign prostatic hyperplasia [J].
Boyle, P ;
Robertson, C ;
Lowe, F ;
Roehrborn, C .
UROLOGY, 2000, 55 (04) :533-539